Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene

• DOI: 10.1007/s10549-023-07170-0
• Publication Date: 2023-12-07T02:01:47Z
• Authors: Shaymaa M. M. Yahya; Heba K. Nabih; Ghada H. Elsayed; Shimaa Ibrahim Ab...; Asmaa M. Elfiky; Sohair M. Salem
• Keywords: Cancer Research; MicroRNA Regulation in Cancer and Development; ABCC1; Breast Neoplasms; Cancer cell; Cancer research; Transporter; Gene; Metastasis; Breast cancer; Cell Line, Tumor; Biochemistry, Genetics and Molecular Biology; ATP-binding cassette transporter; Genetics; Humans; Biogenesis and Functions of Circular RNAs; Molecular Biology; Biology; Cancer; Original Laboratory Investigation; microRNA; Mechanisms and Applications of RNA Interference; Life Sciences; Gene silencing; Gene Expression Regulation, Neoplastic; MicroRNAs; Doxorubicin; Drug Resistance, Neoplasm; Drug resistance; FOS: Biological sciences; Disease Progression; MCF-7 Cells; Female; Multidrug Resistance-Associated Proteins

Abstract Purpose Breast cancer is one of the leading types of cancer diagnosed in women. Despite the improvements in chemotherapeutic cure strategies, drug resistance is still an obstacle leading to disease aggressiveness. The small non-coding RNA molecules, miRNAs, have been implicated recently to be involved as regulators of gene expression through the silencing of mRNA targets that contributed to several cellular processes related to cancer metastasis. Hence, the present study aimed to investigate the beneficial role and mechanism of miRNA-34a-based gene therapy as a novel approach for conquering drug resistance mediated by ATP-binding cassette (ABC) transporters in breast cancer cells, besides exploring the associated invasive behaviors.

Material and Methods Bioinformatics tools were used to predict miRNA ABC transporter targets by tracking the ABC transporter pathway. After the establishment of drug-resistant breast cancer MCF-7 and MDA-MB-231 sublines, cells were transfected with the mimic or inhibitor of miRNA-34a-5p. The quantitative expression of genes involved in drug resistance was performed by QRT-PCR, and the exact ABC transporter target specification interaction was confirmed by dual-luciferase reporter assay. Furthermore, flow cytometric analysis was utilized to determine the ability of miRNA-34a-treated cells against doxorubicin uptake and accumulation in cell cycle phases. The spreading capability was examined by colony formation, migration, and wound healing assays. The apoptotic activity was estimated as well.

Results Our findings firstly discovered the mechanism of miRNA-34a-5p restoration as an anti-drug-resistant molecule that highly significantly attenuates the expression of ABCC1 via the direct targeting of its 3′- untranslated regions in resistant breast cancer cell lines, with a significant increase of doxorubicin influx by MDA-MB-231/Dox-resistant cells. Additionally, the current data validated a significant reduction of metastatic potentials upon miRNA-34a-5p upregulation in both types of breast cancer-resistant cells.

Conclusion The ectopic expression of miRNA-34a ameliorates the acquired drug resistance and the migration properties that may eventually lead to improved clinical strategies and outcomes for breast cancer patients. Additionally, miRNA-34a could be monitored as a diagnostic/prognostic biomarker for resistant conditions.